BACKGROUND/OBJECTIVES: Zinc (Zn) supplementation adversely affects iron status in animal and adult human studies, but few trials have included young infants. The objective of this study was to determine the effects of Zn and multivitamin (MV) supplementation on infant hematologic and iron status. SUBJECTS/METHODS: In a double-blind RCT, Tanzanian infants were randomized to daily, oral Zn, MV, Zn and MV or placebo treatment arms at the age of 6 weeks of life. Hemoglobin concentration (Hb) and red blood cell indices were measured at baseline and at 6, 12 and 18 months of age. Plasma samples from 589 infants were examined for iron deficiency (ID) at 6 months. RESULTS: In logistic regression models, Zn treatment was associated with greater odds of ID (odds ratio (OR) 1.8 (95% confidence interval (CI) 1.0-3.3)) and MV treatment was associated with lower odds (OR 0.49 (95% CI 0.3-0.9)). In Cox models, MV was associated with a 28% reduction in risk of severe anemia (hazard ratio (HR) = 0.72 (95% CI 0.56-0.94)) and a 26% reduction in the risk of severe microcytic anemia (HR = 0.74 (0.56-0.96)) through 18 months. No effects of Zn on risk of anemia were seen. Infants treated with MV alone had higher mean Hb (9.9 g/dl (95% CI 9.7-10.1)) than those given placebo (9.6 g/dl (9.4-9.8)) or Zn alone (9.6 g/dl (9.4-9.7)). CONCLUSIONS: MV treatment improved iron status in infancy, whereas Zn worsened iron status but without an associated increase in risk for anemia. Infants in long-term Zn supplementation programs at risk for ID may benefit from screening and/or the addition of a MV supplement.
INTRODUCTION
Iron deficiency, alone or with resulting anemia, continues to be the most prevalent micronutrient deficiency in the world. 1, 2 It is associated with poor cognitive function, decreased work performance and an increase in the frequency of low birth weight, prematurity and perinatal mortality. Adverse effects of zinc (Zn) supplementation on iron status have been demonstrated in a number of animal and adult human studies including lowered iron absorption, hemoglobin (Hb) and serum ferritin concentrations. [3] [4] [5] [6] The Dietary Reference Intakes (DRI) lists disruptions in iron metabolism as one of the early signs of excessive Zn intake. 7 The impact of Zn supplementation on iron status in children is less clear, as the results of clinical trials examining interactions between iron and Zn have varied widely. Hb and ferritin improve more when iron is given alone than when paired with Zn supplementation. 8, 9 However, two meta-analyses have concluded that Zn supplementation has not been shown to decrease Hb or ferritin concentrations in children. 10, 11 Of note, few trials have included infants age 6 months or younger.
In contrast to the potential negative effects of Zn on iron status, we and others have shown that multivitamin (MV) supplementation has beneficial effects on Hb in young children in resourcelimited settings. Two large trials among young infants, one in multiple countries 12 and another in a malaria endemic region, 13 found that supplementation with multiple micronutrients was more effective than iron alone in the prevention and treatment of anemia. In secondary analyses of a randomized trial in infants born to HIV-infected women in Tanzania, we found that daily MV supplementation (vitamin B complex, C and E) from ages 6 weeks to 25.5 months led to higher Hb concentrations and lower risk for anemia when compared with placebo. 14 We conducted a trial comparing the effects of daily supplementation with Zn, MV, combination Zn and MV or placebo from ages 6 weeks to 19.5 months on infectious morbidity in infants born to HIV-negative mothers in Dar es Salaam, Tanzania. 15 In secondary analyses of data from this study, we aimed to examine effects of Zn and MV supplementation on infant iron and hematologic status.
PATIENTS AND METHODS

Study design and participants
This study is a secondary analysis of a randomized, double-blind, 2 × 2 factorial design trial. 15 Consenting HIV-negative mothers were enrolled shortly after or before delivery and their infants were randomized between 5-7 weeks of life. The sample size was chosen based on power calculations for the primary end points of the parent study (# lower respiratory illness episodes/year). Exclusion criteria were: multiple births, congenital anomalies and other conditions that would interfere with the study procedures.
All study procedures were approved by the Harvard TH Chan School of Public Health Human Subjects Committee, the Muhimbili University of Health and Allied Science Senate Research and Publications Committee, the Tanzanian National Institute of Medical Research, and the Tanzanian Food and Drugs Authority. All mothers provided written informed consent.
Randomization and masking
Infants were randomly assigned to receive one of four daily oral regimens for 18 months from the date of randomization: (1) Zn; (2) MV; (3) Zn+MV and (4) Placebo. A randomization list (1-2400) was created by a biostatistician using blocks of 20 with stratification by study clinic. Supplements were manufactured by Nutriset (Malaunay, France), prepared as an orange-flavored powder in opaque gelatinous capsules. In field testing, all four regimens were found to be indistinguishable in taste, smell and appearance. All study personnel and participants remained blinded to treatment assignment for the duration of the study.
Procedures
Infants received one capsule per day from randomization through 6 months of age, and two capsules/day from 7 months of age to end of follow-up. The capsule provided to infants in the Zn group contained 5 mg zinc sulfate (ZnSO 4 ). The capsule provided to the MV group contained 60 mg vitamin C, 8 mg vitamin E, 0.5 mg vitamin B1, 0.6 mg vitamin B2, 4 mg niacin, 0.6 mg vitamin B6, 130 μg folate and 1 μg vitamin B12. The MV+Zn group received the micronutrients listed in both the MV and Zn groups in a single capsule. Supplement dosing was chosen to maximize the likelihood of seeing an impact of supplementation (with doses substantially above the recommended dietary allowance), while staying within a range considered safe for young children. From ages 0-6 months, doses were between 150 and 600% of the recommended dietary allowance or adequate intake; from 7-12 months of age, 200-400% of the recommended dietary allowance or adequate intake. These doses were consistent with those used in our previous trial of MV supplementation of HIV-exposed children. 8 Mothers and children were followed for 18 months from the date of randomization or until the child's death or loss to followup. Mothers and children returned to the study clinic every 4 weeks for data collection and standard clinical care. Demographic data were obtained in interviews with the mother at recruitment and monthly follow-up visits. Birth data were collected from medical records.
Iron and hematologic status
Complete blood count assays were performed on venous blood draws at randomization and ages 6, 12 and 18 months using the AcT5 Diff AL hematology analyzer (Beckman Coulter, Jersey City, NJ, USA). Plasma ferritin, alpha-1-acid glycoprotein (AGP) and soluble transferrin receptor (sTfR) were measured using an enzyme-linked immunosorbent assay (ELISA) 16 in samples drawn at age 6 months and frozen at − 80°C from a subset of infants (n = 589) as part of a separate study of enteric dysfunction and growth. To be eligible for those analyses, children were required to have a blood sample available at 6 weeks of life and 6 months of age, and have a length-for-age Z-score (LAZ) ⩾ − 2 at 6 weeks of age.
Anemia was defined as Hb concentration o 10.0 g/dl at baseline (6 weeks of age) and o11.0 g/dl during follow-up, and severe anemia was defined as Hb o8.5 g/dl at any age. 17 Microcytosis was defined as mean corpuscular volume (MCV)o70 fl. 17 Iron deficiency was defined as ferritin o12 μg/l or in cases where AGP ⩾ 1.0 g/l, sTfR48.3 mg/l. 18 
Statistical analyses
Children with Hb measured at baseline and at least one follow-up Hb measure were included in analyses (N = 2006). χ 2 -tests were used to examine the proportion of infants with iron deficiency at age 6 months in each treatment arm. Analysis of variance was used to compare mean Hb, ferritin and sTfr between treatment arms at age 6 months. Logistic regression models were used to examine treatment effects on odds of developing iron deficiency at 6 months of age. Cox proportional hazard models were used to examine treatment effects on the risk of developing anemia and anemia subtypes (for example, severe, microcytic) during follow-up. We excluded children who had anemia (remaining n = 1387) or severe anemia (remaining n = 1930) at baseline from the respective analyses conducted to determine the risk of developing anemia and anemia subtypes. Analysis of variance models with Bonferroni correction for post hoc comparisons were used to compare Hb among different treatment groups at baseline and ages 6, 12 and 18 months. Analyses were conducted in SAS software Version 9.1 (SAS Institute, Cary, NC, USA). Twosided P-values o 0.05 were considered statistically significant.
RESULTS
Among infants who met criteria for Hb analyses, sample characteristics were similar between treatment regimen arms ( Table 1) . Baseline characteristics were similar between infants with (n = 2006) and without (n = 394) sufficient Hb values to be included in Hb analyses and similar between infants selected for iron status assays at 6 months of age (n = 589) and the rest of the cohort, with the exception of age at randomization. Infants with 6month iron status values were 0.4 (95% confidence interval (CI) 0.1-0.7) days younger at enrollment than those without iron status values. Baseline demographic and birth characteristics are also shown in Table 1 . Baseline Hb values were similar between treatment arms. Table 2 compares iron status indicators at 6 months of age among treatment arms. Infants treated with MV alone had the lowest prevalence of iron deficiency, whereas those treated with Zn alone had the highest. There were no differences among treatment arms in mean ferritin, ferritin adjusted for AGP and sTfR. In logistic regression models, Zn treatment was associated with greater odds of iron deficiency ((odds ratio 1.8 (95% CI 1.0-3.3); P o0.05) and MV treatment was associated with lower odds (odds ratio 0.49 (95% CI 0.3-0.9); Po 0.05).
In Cox models, neither MV nor Zn treatment were associated with increased risk of developing anemia or microcytic anemia during the follow-up period (Table 3 ). However, MV use was associated with a 28% reduction in the risk of severe anemia (hazard ratio = 0.72 (95% CI 0.56-0.94)) and a 26% reduction in the risk of severe microcytic anemia (hazard ratio = 0.74 (95% CI 0.56-0.96)) through 18 months of age. No effects of Zn on risk of severe anemia or severe microcytic anemia were seen. No interaction effects were seen for sex, low birth weight, preterm delivery or baseline Hb (data not shown).
Infants treated with MV alone had higher mean Hb than those given Zn alone at 12 months (9.9 vs 9.6 g/dl, P ⩽ 0.05) and 18 months (9.9 vs 9.6 g/dl, P ⩽ 0.05) ( Table 4 ). Infants treated with MV alone had higher mean Hb than those given placebo at 18 months (9.9 vs 9.6 g/dl, P ⩽ 0.05). In linear regression models including both MV and Zn treatment, MV treatment was associated with an increase in Hb of 0.2 g/dl (P ⩽ 0.01) at 12 months and 0.3 g/dl (P ⩽ 0.001) at 18 months. No differences in Hb values between infants treated with Zn and those with placebo or Zn+MV therapy were observed at any age.
DISCUSSION
In this trial among young infants comparing the effects of daily supplementation with Zn, MV, Zn plus MV or placebo from 6 weeks to 18 months of age, Zn treatment was associated with a higher risk of iron deficiency at 6 months, but no long-term increase in risk of anemia, whereas MV treatment was associated with a lower risk of both iron deficiency and anemia. These findings are potentially important as Zn supplementation programs are increasingly implemented in global health initiatives.
Our finding that Zn treatment was not associated with changes in Hb or risk of anemia is consistent with earlier studies that have failed to show effects of Zn supplementation on Hb concentrations in children. 10, 11, 19 However, the odds of developing iron deficiency at 6 months of age were increased by over 80% in infants treated with Zn, suggesting that Zn treatment for 18 months may worsen iron status, but not to a degree severe enough to affect Hb production. Anemia is a late marker of iron deficiency, as iron is preferentially shunted to Hb production from tissues, including the brain, until iron deficiency becomes severe. Furthermore, iron deficiency without anemia during infancy has been associated with delays in cognitive and socio-emotional development, some of which are irreversible. [20] [21] [22] [23] The importance of the age at which the effect of Zn was seen, 6 months, is underscored by the fact that most public health iron deficiency screening programs begin at 9 or 12 months of age. Future studies are needed to determine whether and how the duration and/or dosage level of Zn treatment are needed before the risk of iron deficiency increases.
Previous clinical trials of iron and Zn supplementation in children have also addressed this issue. Among Mexican preschoolers, iron plus Zn increased serum ferritin less than iron alone. 9 In Indonesia, Values are means ± s.d. or n (%). There were no differences in any baseline characteristics between groups (all P-values40.05). b From a list that includes sofa, television, radio, refrigerator and fan.
Effects of zinc and multivitamins on infant iron status the combination of both Zn (10 mg/d) and iron (10 mg/d) in infants was less effective than iron alone in reducing the occurrence of anemia. 8 The effects of Zn treatment on iron status may be the result of competitive inhibition of iron absorption or utilization. Evidence suggests that Zn may compete with iron at two levels: the divalent metal transporter-1 (DMT-1) (the protein responsible for importing ferrous iron into the apical membranes of the gastrointestinal epithelial cell) and ferroportin (FPN) (the regulator of iron efflux across the basolateral membrane). Competitive inhibition of iron at these sites would thus reduce transfer of dietary iron to the bloodstream. In adult humans, Zn supplementation has been shown to reduce absorption of radio-labeled iron when the weight ratio of Zn dietary intake to iron dietary intake exceeded 5:1. 6 For infants who were mostly breastfed, this ratio may have been easily exceeded by the Zn supplementation dosage provided in this study given the relatively low iron content of breastmilk. The Zn compound used may impact potential effects on iron absorption. In a study of Indonesian school-aged children, iron absorption from flour fortified with both iron and zinc oxide was superior to flour fortified with iron and zinc sulfate, the compound used in the current study. 24 Although early iron status is largely dependent on fetal iron stores, complementary feeding was started before 2 months in this cohort on average (with no differences between treatment arms), making potential disruptions in intestinal iron absorption potentially more impactful. Other measured risk factors for iron deficiency, such as premature delivery and low birth weight, were similar between treatment arms. Unmeasured potential factors affecting prenatal and infant iron status include maternal iron status and lack of delayed cord clamping, but given the RCT study design, these factors were likely evenly distributed among treatment arms. Moreover, there were no group differences in baseline Hb concentrations among treatment groups.
MV treatment was associated with a 26% lower risk of developing severe anemia and severe microcytic anemia during the follow-up period. The fact that the magnitude of MVassociated risk reduction was similar for severe anemia, which may have many causes, and severe microcytic anemia, which is Abbreviations: ANOVA, analysis of variance; CI, confidence interval; NS, not significant. a Values are NS followed by mean hemoglobin (g/dl) with 95% CI from ANOVA models. b ANOVA post hoc comparison with Bonferroni correction between multivitamin and placebo treatment P ⩽ 0.10. c ANOVA post hoc comparison with Bonferroni correction between multivitamin and zinc treatment P ⩽ 0.05. d ANOVA post hoc comparison with Bonferroni correction between multivitamin and placebo treatment P ⩽ 0.05. mainly caused by iron deficiency, suggests that the beneficial effects of MV treatment on hematologic status were largely due to improved iron status. In addition, MV treatment reduced the odds of developing iron deficiency at 6 months by over 50%. There are several potential mechanisms underlying the benefits of MV supplementation on iron status. Vitamin C enhances intestinal iron absorption. 25 Vitamin C and E both inhibit oxidative damage of erythrocyte cell membranes. 26, 27 B vitamins, particularly riboflavin (B2) and B6, play crucial roles in Hb synthesis, thereby potentially decreasing anemia. 28 These results extend our previous finding of improved hematologic status among infants with vertical HIV exposure treated with the same MV regimen to children without HIV exposure. Of note, both the prevalence of iron deficiency at 6 months of age and Hb concentrations at all ages examined were similar between infants receiving combined MV+Zn treatment and those receiving placebo. Thus, the beneficial effects of MV supplementation on iron status may counterbalance potential detrimental effects of Zn on iron status. Several strengths of our study deserve comment. To our knowledge, our study is the first to examine the effects of Zn and MV supplementation in African infants from 6 weeks of life and one of the first to examine hematologic and iron end points as early as 6 months of life. We used a 2 × 2 factorial double-blinded randomized control design with a large number of participants. Serial hematologic measurements at ages 6, 12 and 18 months allowed us to evaluate the effects of supplementation from 6 months of age, when iron status is generally reflective of fetal iron stores, through the infancy period, when rates of iron deficiency typically increase. Our examination of iron status measures in addition to hematologic measures enabled us to detect effects on iron status even in the absence of effects on Hb production. Furthermore, we examined both ferritin and sTfR, as well as AGP, which allowed us to detect iron deficiency even in the setting of inflammation.
Limitations of this data set also exist. After age 6 months, our measures of iron status were limited to hematologic data, with microcytic anemia as a proxy indicator of iron deficiency. Iron deficiency is the most common cause of microcytic anemia, and while environmental lead exposure and hemoglobinopathies may also cause microcytic anemia, these factors were likely distributed evenly among treatment arms, given the randomized trial design. Given our lack of iron status measures at later ages, we were not able to examine how effects of MV and Zn treatment on iron status may have changed over time. It is unclear whether the lack of an association between MV treatment and non-severe anemia was due to a true lack of effect or inadequate power, since the number of subjects in related analyses was smaller than in the number included in analyses examining severe anemia, in which beneficial effects of MV supplementation were seen. This study did not have an iron supplementation arm, and thus we could not examine potential effects of combination therapy with iron and Zn and/or MVs. Due to limits on blood volumes obtained from infants, biochemical measures of infant Zn status were not available. Potential effects of maternal micronutrient deficiencies, which are common during lactation in Sub-Saharan Africa, 29 were not examined in the current study, but given the RCT study design, such deficiencies were likely evenly distributed among treatment arms.
CONCLUSIONS
In this 2 × 2 factorial double-blind randomized control trial, treatment with MVs was associated with reduced risk of both iron deficiency and severe microcytic anemia, whereas Zn treatment was associated with increased risk of iron deficiency but no longer term increase in risk of anemia. Given the potential for neurodevelopmental sequelae of iron deficiency during infancy, even in the absence of anemia, infants in long-term Zn supplementation programs who are at risk for iron deficiency may benefit from screening and/or the addition of a MV supplement, such as the one studied in this trial.
